855784-26-8Relevant academic research and scientific papers
Cycloaddition Strategies for the Synthesis of Diverse Heterocyclic Spirocycles for Fragment-Based Drug Discovery
King, Thomas A.,Stewart, Hannah L.,Mortensen, Kim T.,North, Andrew J. P.,Sore, Hannah F.,Spring, David R.
, p. 5219 - 5229 (2019/08/12)
In recent years the pharmaceutical industry has benefited from the advances made in fragment-based drug discovery (FBDD) with more than 30 fragment-derived drugs currently marketed or progressing through clinical trials. The success of fragment-based drug
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: Highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate
Yoshida, Ken-ichi,Nakayama, Kiyoshi,Ohtsuka, Masami,Kuru, Noriko,Yokomizo, Yoshihiro,Sakamoto, Atsunobu,Takemura, Makoto,Hoshino, Kazuki,Kanda, Hiroko,Nitanai, Hironobu,Namba, Kenji,Yoshida, Kumi,Imamura, Yuichiro,Zhang, Jason Z.,Lee, Ving J.,Watkins, William J.
, p. 7087 - 7097 (2008/04/12)
A series of 4-oxo-4H-pyrido[1,2-a]pyrimidine derivatives, substituted at the 2-position with piperidines bearing quaternary ammonium salt side chains, were synthesized and evaluated for their ability to potentiate the activity of the fluoroquinolone levofloxacin (LVFX) and the β-lactam aztreonam (AZT) in Pseudomonas aeruginosa. Attachment of the charged entity using an N-ethylcarbamoyloxy linker led to the discovery of the highly soluble compound 22 (D13-9001), which maintained good potency in vitro and displayed excellent activity in vivo in a rat pneumonia model of P. aeruginosa.
USE OF (3-(1-(3-PHENYL-PROPENYL)-PIPERIDIN-4-YL)-2,3-DIHYDRO-INDOL-1-YL)-(PYRIDIN-4-YL)-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INSECTICIDES
-
Page/Page column 137-138, (2010/02/12)
The use of a compound of formula (I): R3 N Y R1(I) wherein Y is a single bond, C=O, C=S or S(O)71 where m is 0, 1 or 2; R1, R2 , R3 , R4, R8 and Ra are specified organ
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
-
, (2008/06/13)
The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
